DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Hardy - 2 Johnson - 1 William Blair - 1 Matt Phipps - 1 Bristol Myers - 1 Johnson's - 1 Merck's Keytruda - 1 J's Stelara - 1
Top related locs:
Europe U.S drugmakers EY Cambridge , Massachusetts Arda EY's Americas Bristol
Top related orgs:
JPMorgan - 2 New York Stock Exchange - 1 Johnson - 1 NYSE Big - 1 Bristol Myers Squibb - 1 Merck - 1 Biden - 1 William Blair & Company - 1

Search resuls for: "Sel Hardy"


3 mentions found


☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
  + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +12 min
Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.
Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC
☆ Retail investors crowd into Eli Lilly after weight-loss drug approval
  + stars: | 2023-11-17 | by ( Bhanvi Satija Amruta Khandekar | Bhanvi Satija | Amruta Khandekar | ) www.reuters.com   time to read: +2 min
The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler Acquire Licensing RightsNov 17 (Reuters) - Retail flows into Eli Lilly (LLY.N) spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Lilly and Novo Nordisk (NOVOb.CO) - seen as leaders in a potential $100 billion obesity treatment market - have helped rekindle retail investor interest in the healthcare sector. "During the COVID period, retail investors were piling into healthcare because of the vaccines and after that there was a bit of a hangover of purchases. Reuters GraphicsRetail investors are now "catching up" with institutional investors, said Sel Hardy, vice president of equity research at CFRA.
Persons: Lilly, Eli Lilly, Vincent Kessler, Zepbound, Marco Iachini, Hardy, JPMorgan Chase, Vanda, Ozempic, drugmakers, Iachini, Bhanvi Satija, Sriraj Organizations: REUTERS, U.S . pharma, Vanda Research, Novo Nordisk, Graphics Retail, Sel Hardy, JPMorgan, BlackRock, AMC, Thomson Locations: Lilly France, Fegersheim, Strasbourg, France, U.S, Bengaluru
☆ Some demand for energy in Europe could be 'lost forever' after a terrible year for oil and gas, exec says
  + stars: | 2023-10-17 | by ( Phil Rosen | ) www.businessinsider.com   time to read: +2 min
Some of the lost demand for energy in Europe may be gone for good, the CEO of Vitol said. Global gas prices soared in 2022 after Russia cut off its gas supply to Europe, disrupting the energy sector. "We can expect some of that lost demand to stay lost forever." AdvertisementAdvertisementTurmoil and soaring prices in the energy sector have crimped demand in Europe, and the chief executive of Vitol warned that some of that demand may never return. Hardy, speaking at the Energy Intelligence Forum, added: "We can expect some of that lost demand to stay lost forever."
Persons: Vitol, —, Russel Hardy, Hardy, Fatih Birol, Birol Organizations: Global, Service, Reuters, Energy Intelligence, International Energy Agency, Financial Times Locations: Europe, Russia, London, Ukraine, Moscow, Israel
0 next >>
Total: 3